Puma Biotechnology, Inc. PBYI
10.62 USD -0.07 (-0.70%)
Nov 5, 2026, 10:19 AM EST
10.39 Day range 10.88
4.58 52-week range 11.50
- YTD
- +78.40%
- 1 year
- +114.44%
News
businesswire.com Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) LOS ANGELES--(BUSINESS WIRE)--Puma biotechnology reported that it granted inducement awards in October 2026, as required under Nasdaq Listing Rule 5635(c)(4).
benzinga.com Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript On Thursday, Puma Biotechnology (NASDAQ:PBYI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
benzinga.com Puma Biotechnology Initiates ALISertib In CAncer Phase II Trial Of Alisertib In Combination With Paclitaxel For Treatment Of Patients With Advanced Small Cell Lung Cancer Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in…
benzinga.com TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6 TD Cowen analyst Marc Frahm maintains Puma Biotechnology (NASDAQ:PBYI) with a Hold and raises the price target from $5 to $6.
benzinga.com Puma Biotechnology Sees Q3 Sales $56.000M-$59.000M vs $60.500M Est Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $56.000 million-$59.000 million vs $60.500 million analyst estimate.- benzinga.com Puma Biotechnology Raises FY2026 Sales Guidance from $222.000M-$229.000M to $224.000M-$231.000M vs $222.000M Est Puma Biotechnology (NASDAQ:PBYI) raises FY2026 sales outlook from $222.000 million-$229.000 million to $224.000 million-$231.000 million vs $222.000 million estimate.
benzinga.com Puma Biotechnology Q2 Adj. EPS $0.19 Beats $0.04 Estimate, Sales $53.600M Beat $53.000M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.04 by 375 percent. This is a 26.67 percent increase over earnings of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals…
benzinga.com Puma Biotechnology Sees Q2 Sales $52.000M-$55.000M vs $52.000M Est Second Quarter and Full Year 2026 Financial Outlook Second Quarter2026NewFull Year 2026PriorFull Year 2026Net Product Revenue$50–$52 million$202-206 million$194–$198 millionRoyalty Revenue$2–$3…- benzinga.com Puma Biotechnology Raises FY2026 Sales Guidance from $214.000M-$221.000M to $222.000M-$229.000M vs $218.000M Est Second Quarter and Full Year 2026 Financial Outlook Second Quarter2026NewFull Year 2026PriorFull Year 2026Net Product Revenue$50–$52 million$202-206 million$194–$198 millionRoyalty Revenue$2–$3…
benzinga.com Puma Biotechnology Q1 Adj. EPS $(0.04) Beats $(0.13) Estimate, Sales $44.800M Beat $42.000M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.13) by 69.23 percent. This is a 140 percent decrease over earnings of…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com UPDATE: Puma Biotechnology Sees FY2026 Sales $214.000M-$221.000M vs $220.000M Est Puma Biotechnology (NASDAQ:PBYI) sees FY2026 sales of $214.000 million-$221.000 million vs $220.000 million analyst estimate.
benzinga.com UPDATE: Puma Biotechnology Q4 Adj. EPS $0.29 Beats $0.23 Estimate, Sales $75.500M Beat $68.600M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.23 by 27.75 percent. This is a 32.56 percent decrease over earnings of…- benzinga.com Puma Biotechnology Sees Q1 Sales $38.000M-$42.000M vs $49.000M Est Puma Biotechnology (NASDAQ:PBYI) sees Q1 sales of $38.000 million-$42.000 million vs $49.000 million analyst estimate.
benzinga.com Puma Biotechnology Sees FY2026 Sales $214.000-$221.000M vs $220.000M Est Puma Biotechnology (NASDAQ:PBYI) sees FY2026 sales of $214.000-$221.000 million vs $220.000 million analyst estimate.
benzinga.com Puma Biotechnology Q4 Earnings Report: What Investors Need to Know 
benzinga.com Puma Biotechnology Q4 Adj. EPS $0.30 Beats $0.23 Estimate, Sales $75.500M Beat $68.600M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.23 by 32.16 percent. This is a 30.23 percent decrease over earnings of…
benzinga.com Earnings Scheduled For February 26, 2026 - benzinga.com Puma Biotechnology Added To Nasdaq Biotechnology Index, Effective Dec. 19 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective at the close of trading on Friday,…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Puma Biotechnology Raises FY2025 Sales Guidance from $212.000M-$222.000M to $220.000M-$223.000M vs $216.500M Est Puma Biotechnology (NASDAQ:PBYI) raises FY2025 sales outlook from $212.000 million-$222.000 million to $220.000 million-$223.000 million vs $216.500 million estimate.
- benzinga.com Puma Biotechnology Sees Q4 Sales $67.000M-$70.000M vs $66.600M Est Puma Biotechnology (NASDAQ:PBYI) sees Q4 sales of $67.000 million-$70.000 million vs $66.600 million analyst estimate.
- benzinga.com Puma Biotechnology Q3 Adj. EPS $0.21 Beats $0.04 Estimate, Sales $54.500M Beat $51.000M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.04 by 366.67 percent. This is a 53.33 percent decrease over earnings of…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Puma Biotechnology Affirms FY2025 Sales Guidance of $212.000M-$222.000M vs $217.800M Est Puma Biotechnology (NASDAQ:PBYI) affirms FY2025 sales outlook from $212.000 million-$222.000 million to $212.000 million-$222.000 million vs $217.800 million estimate.
- benzinga.com Puma Biotechnology Sees Q3 Sales $48.000M-$51.000M vs $60.000M Est Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $48.000 million-$51.000 million vs $60.000 million analyst estimate.
- benzinga.com Puma Biotechnology Q2 Adj. EPS $0.15 Beats $0.10 Estimate, Sales $49.20M Miss $50.75M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 45.63 percent. This is a 400 percent increase over losses of…
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Puma Biotechnology Q1 Adj. EPS $0.10 Beats $(0.02) Estimate, Sales $46.00M Beat $44.55M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.02) by 600 percent. This is a 300 percent increase over losses of…
- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $7 price target.
- benzinga.com Puma Biotechnology Sees Q1 Sales $42.500M-$45.500M vs $47.50M Est Puma Biotechnology (NASDAQ:PBYI) sees Q1 sales of $42.500 million-$45.500 million vs $47.50 million analyst estimate.
- benzinga.com Puma Biotechnology Sees FY2025 Sales $212.000M-$222.000M vs $207.90M Est Puma Biotechnology (NASDAQ:PBYI) sees FY2025 sales of $212.000 million-$222.000 million vs $207.90 million analyst estimate.
- benzinga.com Puma Biotechnology Q4 Adj EPS $0.43 Beats $0.10 Estimate, Sales $59.10M Beat $52.50M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.10 by 330 percent. This is a 38.71 percent increase over earnings of…
- benzinga.com Earnings Scheduled For February 27, 2025
- benzinga.com Earnings Scheduled For February 29, 2024 Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Earnings Scheduled For November 2, 2023 Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
benzinga.com Earnings Scheduled For August 3, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.- benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
- benzinga.com Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront…
- benzinga.com Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
- benzinga.com Earnings Scheduled For March 2, 2023 Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
- benzinga.com Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 50 stocks hit new 52-week highs.
- benzinga.com Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday Gainers
- benzinga.com Earnings Scheduled For November 3, 2022 Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
- benzinga.com Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate Here's a roundup of top developments in the biotech space over the last 24 hours:
- benzinga.com Earnings Scheduled For August 4, 2022 Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.